<?xml version="1.0" ?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
<bibl type="article" xml:id="b0">
	<analytic>
		
		<author>
			<persName><forename type="first">V</forename><forename type="middle">Maruti</forename><surname>Patil</surname></persName>
		</author>
		<author>
			<persName><forename>V</forename><surname>Noronha</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Joshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Choughule</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Bhattacharjee</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Goud</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>More</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Ramaswamy</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Karpe</surname></persName>
		</author>
		<author>
			<persName><forename>N</forename><surname>Pande</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Chandrasekharan</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Goel</surname></persName>
		</author>
		<title level="a">Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma</title>
	</analytic>
	<monogr>
		<title level="j">ESMO Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e000168</biblScope>
			<date when="2017">2017</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b1">
	<analytic>
		
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename>Y</forename><surname>Ohe</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Reungwetwattana</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Chewaskulyong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Dechaphunkul</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Imamura</surname></persName>
		</author>
		<author>
			<persName><forename>N</forename><surname>Nogami</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Kurata</surname></persName>
		</author>
		<author>
			<persName><forename>I</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Cho</surname></persName>
		</author>
		<title level="a">Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="113" to="125" />
			<date when="2018">2018</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b2">
	<analytic>
		
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Felip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Syrigos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Göker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Georgoulias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Isla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Guclu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Morabito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Min</surname></persName>
		</author>
		<author>
			 LUX-Lung 8 Investigators
		</author>
		<title level="a">Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial</title>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol.</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="897" to="907" />
			<date when="2015">2015</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b3">
	<analytic>
		
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Ettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Aisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename>W</forename><surname>Akerley</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Bauman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Chirieac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>D'Amico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Dilling</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Dobelbower</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Govindan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gubens</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Hennon</surname></persName>
		</author>
		<title level="a">NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018</title>
	</analytic>
	<monogr>
		<title level="j">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="807" to="821" />
			<date when="2018">2018</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b4">
	<analytic>
		
		<author>
			<persName><forename>S</forename><surname>Novello</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Barlesi</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Califano</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Cufer</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Ekman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Giaj</forename><surname>Levra</surname></persName>
		</author>
		<author>
			<persName><forename>K</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Popat</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Senan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Simo</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Peters</surname></persName>
		</author>
		<title level="a">ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol.</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="v1" to="v27" />
			<date when="2016">2016</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b5">
	<analytic>
		
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>von Pawel</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Biesma</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Manegold</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Serwatowski</surname></persName>
		</author>
		<author>
			<persName><forename>U</forename><surname>Gatzemeier</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Digumarti</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Zukin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Mellemgaard</surname></persName>
		</author>
		<author>
			<persName><forename>K</forename><surname>Park</surname></persName>
		</author>
		<title level="a">Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol.</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3543" to="3551" />
			<date when="2008">2008</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b6">
	<analytic>
		
		<author>
			<persName><forename>P</forename><surname>Tomasini</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Barlesi</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Mascaux</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Greillier</surname></persName>
		</author>
		<title level="a">Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes</title>
	</analytic>
	<monogr>
		<title level="j">Ther Adv Med Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="198" to="208" />
			<date when="2016">2016</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b7">
	<analytic>
		
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Paz-Ares</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>De Marinis</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Dediu</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pujol</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Bidoli</surname></persName>
		</author>
		<author>
			<persName><forename>O</forename><surname>Molinier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Sahoo</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Laack</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Corral</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Melemed</surname></persName>
		</author>
		<author>
			<persName><forename>W</forename><surname>John</surname></persName>
		</author>
		<title level="a">PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2895" to="2902" />
			<date when="2013">2013</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b8">
	<analytic>
		
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gentzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Patel</surname></persName>
		</author>
		<title level="a">Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications</title>
	</analytic>
	<monogr>
		<title level="j">Ther Adv Med Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="4" to="15" />
			<date when="2014">2014</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b9">
	<analytic>
		
		<author>
			<persName><forename>T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Brodowicz</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Zielinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Krzakowski</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Laack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename>I</forename><surname>Bover</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Begbie</surname></persName>
		</author>
		<author>
			<persName><forename>V</forename><surname>Tzekova</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Cucevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<title level="a">Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="1432" to="1440" />
			<date when="2009">2009</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b10">
	<analytic>
		
		<author>
			<persName><forename>X</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename>G</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename>X</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Ouyang</surname></persName>
		</author>
		<author>
			<persName><forename>Z</forename><surname>Zhao</surname></persName>
		</author>
		<title level="a">Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System</title>
	</analytic>
	<monogr>
		<title level="j">Clin Ther.</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="54" to="65" />
			<date when="2013">2013</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b11">
	<analytic>
		
		<author>
			<persName><forename>K</forename><surname>Matter-Walstra</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Joerger</surname></persName>
		</author>
		<author>
			<persName><forename>U</forename><surname>Kühnel</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Szucs</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Pestalozzi</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Schwenkglenks</surname></persName>
		</author>
		<title level="a">Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System</title>
	</analytic>
	<monogr>
		<title level="j">Value in Health</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="65" to="71" />
			<date when="2012">2012</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b12">
	<analytic>
		
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Chattopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Justice</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Sridhara</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Pazdur</surname></persName>
		</author>
		<title level="a">Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)</title>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1344" to="1351" />
			<date when="2010">2010</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b13">
	<analytic>
		
		<author>
			<persName><forename>F</forename><surname>Cappuzzo</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Stelmakh</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Cicenas</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Szczésna</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Juhász</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Esteban</surname></persName>
		</author>
		<author>
			<persName><forename>O</forename><surname>Molinier</surname></persName>
		</author>
		<author>
			<persName><forename>W</forename><surname>Brugger</surname></persName>
		</author>
		<author>
			<persName><forename>I</forename><surname>Melezínek</surname></persName>
		</author>
		<author>
			<persName><forename>G</forename><surname>Klingelschmitt</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Klughammer</surname></persName>
		</author>
		<author>
			<persName><forename>G</forename><surname>Giaccone</surname></persName>
		</author>
		<author>
			SATURN investigators
		</author>
		<title level="a">Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study</title>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol.</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="521" to="529" />
			<date when="2010">2010</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b14">
	<analytic>
		
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Rodrigues Pereira</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename>V</forename><surname>Hirsh</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Thongprasert</surname></persName>
		</author>
		<author>
			<persName><forename>D</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Maoleekoonpiroj</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Smylie</surname></persName>
		</author>
		<author>
			<persName><forename>R</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>van Kooten</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Dediu</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Findlay</surname></persName>
		</author>
		<author>
			National Cancer Institute of Canada Clinical Trials Group
		</author>
		<title level="a">Erlotinib in Previously Treated Non–Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="123" to="132" />
			<date when="2005">2005</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="book" xml:id="b15">
	<monogr>
		
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Rubin</surname></persName>
		</author>
		<title level="m">Statistical Analysis with Missing Data</title>
		<imprint>
			<publisher>John Wiley &amp; Sons</publisher>
			<pubPlace>Hoboken</pubPlace>
			<date when="2014">2014</date>
		</imprint>
	</monogr>
	<note>2nd Edition</note>
</bibl>

<bibl type="article" xml:id="b16">
	<analytic>
		
		<author>
			<persName><forename>T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Stelmakh</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Cicenas</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Miliauskas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Grigorescu</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Hillenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Johannsdottir</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Klughammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Gonzalez</surname></persName>
		</author>
		<title level="a">Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study</title>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol.</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="300" to="308" />
			<date when="2012">2012</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b17">
	<analytic>
		
		<author>
			<persName><forename>S</forename><surname>Cicènas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Geater</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Petrov</surname></persName>
		</author>
		<author>
			<persName><forename>Y</forename><surname>Hotko</surname></persName>
		</author>
		<author>
			<persName><forename>G</forename><surname>Hooper</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename>N</forename><surname>Mudie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<title level="a">Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)</title>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="30" to="37" />
			<date when="2016">2016</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b18">
	<analytic>
		
		<author>
			<persName><forename>W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Innocenti</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><forename type="last">Jr</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ratain</surname></persName>
		</author>
		<title level="a">Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism</title>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res.</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1009" to="1012" />
			<date when="2003">2003</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b19">
	<analytic>
		
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Phelps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Stinchcombe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Blachly</surname></persName>
		</author>
		<author>
			<persName><forename>W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Schaaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Starrett</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Poi</surname></persName>
		</author>
		<author>
			<persName><forename>D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Papp</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Aimiuwu</surname></persName>
		</author>
		<author>
			<persName><forename>Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Li</surname></persName>
		</author>
		<title level="a">Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses</title>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="182" to="191" />
			<date when="2014">2014</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b20">
	<analytic>
		
		<author>
			<persName><forename>M</forename><surname>Fukudo</surname></persName>
		</author>
		<author>
			<persName><forename>Y</forename><surname>Ikemi</surname></persName>
		</author>
		<author>
			<persName><forename>Y</forename><surname>Togashi</surname></persName>
		</author>
		<author>
			<persName><forename>K</forename><surname>Masago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Mio</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Terada</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Teramukai</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Mishima</surname></persName>
		</author>
		<author>
			<persName><forename>K</forename><surname>Inui</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Katsura</surname></persName>
		</author>
		<title level="a">Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacokinet</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="593" to="609" />
			<date when="2013">2013</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b21">
	<analytic>
		
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rudin</surname></persName>
		</author>
		<author>
			<persName><forename>W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName><forename>T</forename><surname>Karrison</surname></persName>
		</author>
		<author>
			<persName><forename>X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Janisch</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Poonkuzhali</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Schuetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Fackenthal</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		
		<title level="a">Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol.</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1119" to="1127" />
			<date when="2008">2008</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b22">
	<analytic>
		
		<author>
			<persName><forename>J</forename><surname>Brahmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Reckamp</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Baas</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Crinò</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Poddubskaya</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Antonia</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Pluzanski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Vokes</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Holgado</surname></persName>
		</author>
		<author>
			<persName><forename>D</forename><surname>Waterhouse</surname></persName>
		</author>
		<author>
			<persName><forename>N</forename><surname>Ready</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Gainor</surname></persName>
		</author>
		<title level="a">Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="123" to="135" />
			<date when="2015">2015</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b23">
	<analytic>
		
		<author>
			<persName><forename>H</forename><surname>Borghaei</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Paz-Ares</surname></persName>
		</author>
		<author>
			<persName><forename>L</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Spigel</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Steins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Ready</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Q</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Vokes</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Felip</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Holgado</surname></persName>
		</author>
		<author>
			<persName><forename>F</forename><surname>Barlesi</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Kohlhäufl</surname></persName>
		</author>
		<author>
			<persName><forename>O</forename><surname>Arrieta</surname></persName>
		</author>
		<title level="a">Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1627" to="1639" />
			<date when="2015">2015</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b24">
	<analytic>
		
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Herbst</surname></persName>
		</author>
		<author>
			<persName><forename>P</forename><surname>Baas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename>E</forename><surname>Felip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pérez-Gracia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Arvis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename>M</forename><surname>Majem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Fidler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Jr</forename><surname>De Castro</surname></persName>
		</author>
		<title level="a">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="1540" to="1550" />
			<date when="2016">2016</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b25">
	<analytic>
		
		<author>
			<persName><forename>P</forename><surname>Ruff</surname></persName>
		</author>
		<author>
			<persName><forename>S</forename><surname>Al-Sukhun</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Shulman</surname></persName>
		</author>
		<title level="a">Access to Cancer Therapeutics in Low-and Middle-Income Countries</title>
	</analytic>
	<monogr>
		<title level="j">Am Soc Clin Oncol Educ Book</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="58" to="65" />
			<date when="2016">2016</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b26">
	<analytic>
		
		<author>
			<persName><forename type="first">N</forename><forename type="middle">I</forename><surname>Cherny</surname></persName>
		</author>
		<author>
			<persName><forename>U</forename><surname>Dafni</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Latino</surname></persName>
		</author>
		<author>
			<persName><forename>G</forename><surname>Pentheroudakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Douillard</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Tabernero</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Zielinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Piccart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>de Vries</surname></persName>
		</author>
		<title level="a">ESMO-Magnitude of Clinical Benefit Scale version 1.1</title>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2340" to="2366" />
			<date when="2017">2017</date>
		</imprint>
	</monogr>
</bibl>

<bibl type="article" xml:id="b27">
	<analytic>
		
		<author>
			<persName><forename>L</forename><surname>Peeters</surname></persName>
		</author>
		<author>
			<persName><forename>A</forename><surname>Sibille</surname></persName>
		</author>
		<author>
			<persName><forename>B</forename><surname>Anrys</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Oyen</surname></persName>
		</author>
		<author>
			<persName><forename>C</forename><surname>Dooms</surname></persName>
		</author>
		<author>
			<persName><forename>K</forename><surname>Nackaerts</surname></persName>
		</author>
		<author>
			<persName><forename>I</forename><surname>Wauters</surname></persName>
		</author>
		<author>
			<persName><forename>J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<title level="a">Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions</title>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1291" to="1295" />
			<date when="2012">2012</date>
		</imprint>
	</monogr>
</bibl>

				</listBibl>
	</back>
	</text>
</TEI>
